Skip to content

Comparison of Intravenous Colisitin vs Inhalational Colisitin

Comparison of Intravenous Colistin vs inhalational colisitin for gram negative hospital acquired pnumonia

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
TCTR
Registry ID
TCTR20251220002
Enrollment
160
Registered
2025-12-20
Start date
2024-12-15
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gram negative Hospital Acquired Pneumonia HAP Inhaled Colisitin Intravenous Colisitin

Interventions

Patients treated with Intravenous Colisitn,Pateints treated with Inhalational Colisitn
Treatment,Treatment
IV Group,Inhalational Group

Sponsors

Self Funded
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patient of age 18-65 years. Either gender. Patient admitted in ICU / HDU irrespective of reason Patient with hospital-acquired pneumonia. . Patient with gram-negative organism in culture.

Exclusion criteria

Exclusion criteria: Patient admitted with pneumonia. Immunocompromised patient. Patient with renal impairment / chronic Iiver disease,

Design outcomes

Primary

MeasureTime frame
Cure: 14 days Resolution of symptoms/signs of pneumonia

Secondary

MeasureTime frame
Microbiological Response 14 days Tracheal Cultures

Countries

Pakistan

Contacts

Public ContactMuddassir Anis

postgradute resident

muddassiranis@hotmail.com00923362027221

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026